Tirzepatide vs Liraglutide
Comparing newer dual GIP/GLP-1 agonist tirzepatide against first-generation daily GLP-1 agonist liraglutide.
Last updated: January 28, 2026
Tirzepatide
Liraglutide
Overview
Tirzepatide and liraglutide represent different generations of incretin therapy. Liraglutide was among the first successful GLP-1 agonists, while tirzepatide is a newer dual agonist with enhanced efficacy. This comparison illustrates the evolution of metabolic peptide therapeutics.
Understanding these differences helps contextualize treatment options and the progress in GLP-1-based therapies.
Key Facts
| Aspect | Tirzepatide | Liraglutide |
|---|---|---|
| Developer | Eli Lilly | Novo Nordisk |
| Generation | Next-generation | First-generation |
| Mechanism | GIP + GLP-1 dual agonist | GLP-1 single agonist |
| Brands | Mounjaro, Zepbound | Victoza, Saxenda |
Mechanism Comparison
| Aspect | Tirzepatide | Liraglutide |
|---|---|---|
| GLP-1 Activity | Agonist | Agonist (primary) |
| GIP Activity | Agonist | None |
| Receptor Targets | GIPR + GLP-1R | GLP-1R only |
| Half-life | ~5 days | ~13 hours |
Tirzepatide Mechanism
- Single molecule activating both GIP and GLP-1 receptors
- GIP amplifies insulin secretion and may improve adipose function
- Synergistic effects beyond GLP-1 monotherapy
- Enhanced weight loss through dual pathways
Liraglutide Mechanism
- 97% homology to native GLP-1
- Fatty acid chain enables albumin binding
- Extended half-life compared to native GLP-1
- Single receptor mechanism
Efficacy Comparison
Weight Loss
| Metric | Tirzepatide (15mg) | Liraglutide (3mg) |
|---|---|---|
| Trial | SURMOUNT-1 | SCALE Obesity |
| Mean Weight Loss | -22.5% | -8.0% |
| ≥10% Weight Loss | 91% | 63.2% |
| ≥15% Weight Loss | 78% | 33.1% |
| ≥20% Weight Loss | 57% | ~14% |
HbA1c Reduction
| Metric | Tirzepatide | Liraglutide |
|---|---|---|
| Max Reduction | -2.3% | -1.5% |
| Target under 7% | ~90% | ~60% |
Note: These are cross-trial comparisons with different populations.
Administration Comparison
| Aspect | Tirzepatide | Liraglutide |
|---|---|---|
| Injections/month | 4 | 30 |
| Injection Site | Abdomen, thigh, arm | Abdomen, thigh, arm |
| Device | Prefilled pen | Prefilled pen |
Convenience Factor
| Factor | Tirzepatide | Liraglutide |
|---|---|---|
| Weekly burden | 1 injection | 7 injections |
| Adherence | Generally higher | More opportunity to miss doses |
| Flexibility | Same day each week | Same time daily |
Side Effect Profile
Gastrointestinal Effects
| Side Effect | Tirzepatide | Liraglutide |
|---|---|---|
| Nausea | 25-35% | 30-40% |
| Vomiting | 10-20% | 10-15% |
| Diarrhea | 15-25% | 15-20% |
| Constipation | 10-15% | 10-15% |
Discontinuation Due to Side Effects
| Factor | Tirzepatide | Liraglutide |
|---|---|---|
| GI-related | 4-7% | 6-10% |
| Overall | 6-10% | 8-12% |
Cardiovascular Evidence
| Aspect | Tirzepatide | Liraglutide |
|---|---|---|
| CV Outcomes Trial | SURPASS-CVOT (ongoing) | LEADER (completed) |
| CV Benefit Proven | Pending | Yes (13% MACE reduction) |
| Heart Failure | Preliminary positive | Neutral |
LEADER Trial Results (Liraglutide)
- 13% reduction in major adverse cardiovascular events
- 22% reduction in CV death
- Established cardiovascular benefit
Tirzepatide CV Data
- CV outcomes trial ongoing
- SELECT-like outcomes expected
- Preliminary signals positive
Indications and Approvals
| Indication | Tirzepatide | Liraglutide |
|---|---|---|
| Type 2 Diabetes | Mounjaro (FDA approved) | Victoza (FDA approved) |
| Obesity | Zepbound (FDA approved) | Saxenda (FDA approved) |
| CV Risk Reduction | Pending | Yes (Victoza) |
Cost Comparison
| Factor | Tirzepatide | Liraglutide |
|---|---|---|
| List Price | ~$1,000/month | ~$1,000-1,400/month |
| Generic Available | No | No (but older) |
| Insurance Coverage | Expanding | More established |
Patient Selection Considerations
Tirzepatide May Be Preferred When:
- Maximum weight loss is the primary goal
- Weekly dosing is strongly preferred
- Patient has not achieved goals with GLP-1 monotherapy
- Glycemic control needs are substantial
Liraglutide May Be Preferred When:
- Proven cardiovascular benefit is important
- Daily dosing flexibility is desired
- Patient has established success with the medication
- Cost/access considerations favor it
- Pregnancy planning (shorter half-life)
Evidence Quality
| Factor | Tirzepatide | Liraglutide |
|---|---|---|
| Trial Quality | Phase 3, rigorous | Phase 3, rigorous |
| Sample Size | Large (thousands) | Large (thousands) |
| Long-term Data | ~2-3 years | >10 years |
| Real-World Evidence | Emerging | Extensive |
| CV Outcomes | Pending | Proven |
Summary
| Factor | Tirzepatide | Liraglutide |
|---|---|---|
| Mechanism | GIP + GLP-1 | GLP-1 only |
| Evidence Level | High | High |
| Weight Loss | ~22% | ~8% |
| CV Benefit | Pending | Proven |
| Experience | Newer | >10 years |
Key Takeaways
- Tirzepatide is more effective: Approximately 2.5-3x greater weight loss than liraglutide
- Tirzepatide is more convenient: Weekly vs. daily dosing improves adherence
- Liraglutide has more long-term data: Over a decade of real-world experience
- Liraglutide has proven CV benefit: LEADER trial demonstrated cardiovascular protection
- Both are FDA-approved: For diabetes and obesity indications
- Cost is similar: Both remain expensive branded medications
- Choice depends on: Efficacy goals, dosing preference, CV considerations
This comparison is for educational purposes only. Consult a healthcare provider for treatment decisions.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.